Fifteen Massachusetts biotechs went public in the first seven months of this year, surpassing the state’s total for all of 2017 and putting the white-hot sector on a potential record-setting pace, according to a new industry report.

Led by Rubius Therapeutics (RUBY), a Cambridge biotech created by Flagship Pioneering that raised about $277 million in an IPO this summer, the 15 companies attracted nearly $1.7 billion in investments through July, said the report, by the Massachusetts Biotechnology Council, a trade group.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy